← Back to Search

Recombinant Fusion Protein

INZ-701 for Pseudoxanthoma Elasticum (PXE)

Phase 1 & 2
Waitlist Available
Research Sponsored by Inozyme Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 52 weeks (day 1 through safety follow-up visit)
Awards & highlights

Study Summary

This trial will study the safety and tolerability of a new drug, INZ-701, for the treatment of ABCC6 Deficiency, which can cause calcification of arteries and other tissues.

Eligible Conditions
  • Pseudoxanthoma Elasticum
  • ABCC6 Deficiency
  • Generalized Arterial Calcification

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~52 weeks (day 1 through safety follow-up visit)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 52 weeks (day 1 through safety follow-up visit) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Treatment Emergent Adverse Events (TEAEs)
Secondary outcome measures
Area under the Plasma Concentration versus Time Curve (AUC) of INZ-701
Change from Baseline in Plasma Inorganic Pyrophosphate (PPi) Levels
Incidence of Anti-Drug Antibodies (ADAs)
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: INZ-701Experimental Treatment1 Intervention
The study design during the Dose Evaluation Period is a MAD 3+3 with 3 dose cohorts. The planned doses will be 0.2 mg/kg, 0.6 mg/kg, and 1.8 mg/kg administered via subcutaneous injection twice weekly. During the Extension Period, subjects will be administered INZ-701 at the dose and dose schedule assigned in the Dose Evaluation Period. However, the administered dose and dose schedule for a subject may change once the selected dosing regimen has been determined upon completion of the Dose Evaluation Period, at which time all subjects will be assigned to the selected dosing regimen.

Find a Location

Who is running the clinical trial?

IQVIA BiotechIndustry Sponsor
18 Previous Clinical Trials
4,898 Total Patients Enrolled
Inozyme PharmaLead Sponsor
7 Previous Clinical Trials
1,128 Total Patients Enrolled
2 Trials studying Pseudoxanthoma Elasticum
1,030 Patients Enrolled for Pseudoxanthoma Elasticum
Borut Cizman, MDStudy DirectorInozyme Pharma, Inc.
1 Previous Clinical Trials
9 Total Patients Enrolled

Media Library

INZ-701 (Recombinant Fusion Protein) Clinical Trial Eligibility Overview. Trial Name: NCT05030831 — Phase 1 & 2
Pseudoxanthoma Elasticum Research Study Groups: INZ-701
Pseudoxanthoma Elasticum Clinical Trial 2023: INZ-701 Highlights & Side Effects. Trial Name: NCT05030831 — Phase 1 & 2
INZ-701 (Recombinant Fusion Protein) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05030831 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies for those wishing to partake in the clinical trial?

"Correct. According to the clinicaltrials.gov database, this medical study is at present attempting to recruit its participants - with a recruitment start date of September 22nd 2021 and last updated on January 12th 2022 - from one location for a total of nine individuals."

Answered by AI

Are there specific criteria that make a person an ideal candidate for this research?

"This clinical trial is searching for 9 participants who suffer from pseudoxanthoma elasticum and are between 18 to 64 years of age."

Answered by AI

What is the cumulative enrollment of this clinical trial?

"Affirmative. According to clinicaltrials.gov, this trial is currently recruiting patients and was initially posted on September 22nd 2021 before being updated as recently as January 12th 2022. Only 9 participants are needed across the sole site involved in the experiment."

Answered by AI

Is the inclusion criteria for this trial limited to individuals of a certain age or can geriatric patients participate?

"This study is interested in participants who are of legal adult age and under 64 years old."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE
2022. "Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05030831.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top